A recent report published by Infinium Global Research on alzheimer’s drugs market provides an in-depth analysis of segments and sub-segments in global
as well as regional alzheimer’s drugs market. The study also highlights the
impact of drivers, restraints and macro indicators on the global and regional alzheimer’s drugs market over the short term as well as long term. The report is a
comprehensive presentation of trends, forecast and dollar values of global alzheimer’s drugs market. According to the report, the global alzheimer’s drugs market is projected to grow at a CAGR of 7.0% over the forecast period of
2018-2024.
Alzheimer's disease is a
neurological disorder in which the death of brain cells causes memory loss and
cognitive decline. Cholinesterase inhibitors are set to treat symptoms related
to memory, language, thinking, judgment and other thought processes. Alzheimer's
drugs prevent the breakdown of a chemical messenger in the brain. It is the
cause of 60–70% of cases of dementia.
The cholinergic, memantine,
combined drug, and other drugs are used to treat alzheimer's disease. The
presence of high revenue-generating drugs such as Donepezil, Exelon, and
galantamine is a key driver, for the growth of cholinergic drug. Memantine, the
fifth alzheimer's drug, is an NMDA (N-methyl-D-aspartate) receptor antagonist
has dominated the drug class segment due to a large number of patent expiry of
major products and a restricted number of drugs to treat alzheimer's disease.
The rising occurrence of
neurodegenerative diseases among the elderly and healthy support from
governments across developed countries have led to the development of new drugs
and therapies which have helped in the development and growth of the alzheimer’s drugs market. Additionally, lack of Duchenne muscular dystrophy (DMD) is another factor that promotes the growth of the market. The lack of DMDs extends the
treatment schedule for alzheimer's disease, which in turn, increases the healthcare costs
for patients.
Among the regions, North America
is expected to the largest market for alzheimer's drugs. A large number of
patients suffering from alzheimer's disease, high purchasing power for
expensive drugs and compensation policies for the treatment of this disease is
likely to boost the growth in this market. The increasing awareness about
neurodegenerative diseases in the Asia-Pacific region will boost the growth of the
global alzheimer’s drugs market in the next coming years.
The report on global alzheimer’s drugs market covers segments
such as drug class and distribution channel. On the basis of drug class, the global alzheimer’s drugs market is
categorized into cholinergic, memantine, combined drug and others. On the basis
of the distribution channel, the global alzheimer’s drugs market is categorized into
hospital pharmacy, retail pharmacy, and online pharmacy.
The report provides regional analysis covering geographies such
as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period
of 2016-2024. The countries covered in the North America region include the
U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India,
South Korea, Malaysia, and among others. Moreover, Germany, U.K., France,
Spain and Rest of Europe are included in the European region. The U.S. drives
the growth in the North America region as it is the largest market in the
region. The Asia-Pacific region offers a substantial potential for the market
growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience a
growth at a CAGR of x.x% over the period of -.
The report provides profiles of the companies in the global alzheimer’s drugs market such as H Lundbeck A/S, Eisai Co Ltd, Ono Pharmaceutical, Daiichi
Sankyo Company Limited, Johnson & Johnson, Merz Holding GmbH & Co KG
and Others.
The report provides deep insights on demand forecasts, market
trends, and micro and macro indicators. In addition, this report provides
insights into the factors that are driving and restraining the global alzheimer’s drugs market. Moreover, IGR-Growth Matrix analysis given in the report brings
an insight into the investment areas that existing or new market players can
consider. The report provides insights into the market using analytical tools
such as Porter's five forces analysis and DRO analysis of alzheimer’s drugs market.
Moreover, the study highlights current market trends and provides forecast from
2018-2024. We also have highlighted future trends in the alzheimer’s drugs market that will impact the demand during the forecast period. Moreover, the
competitive analysis given in each regional market brings an insight into the
market share of the leading players. This report will help manufacturers,
suppliers, and distributors of alzheimer’s drugs market to understand the
present and future trends in this market and formulate their strategies
accordingly.
Please Choose One of them.